Molecular targeted therapy has the same limitation, despite significantly enhanced cancer control and resulting prolonged survival, especially when cancers with driver mutations are treated with specific inhibitors, for example, when non-small cell lung cancer with an epidermal growth factor-receptor (EGFR) mutation is treated by EGFR-tyrosine kinase inhibitors (TKIs) (1). The gene discussed is EGFR; the disease is cancer.